<DOC>
	<DOCNO>NCT03089281</DOCNO>
	<brief_summary>The primary objective evaluate benefit SmartDelay™ algorithm patient prolong RV-LV interval .</brief_summary>
	<brief_title>Strategic Management Optimize Response To Cardiac Resynchronization Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject must indicate receive de novo quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator ( CRTD ) conjunction ACUITY X4 LV lead . This include subject indicate receive upgrade BSC X4 CRTD previously implant device . In order achieve homogenous population study , qualify subject heart failure meet BSC US indication use define subject receive stable optimal pharmacologic therapy ( OPT ) heart failure meet one follow classification : Moderate severe heart failure ( NYHA Class IIIIV ) EF ≤ 35 % QRS duration ≥ 120 m Left bundle branch block ( LBBB ) QRS duration ≥ 130 m , EF ≤ 30 % , mild ( NYHA Class II ) ischemic nonischemic heart failure asymptomatic ( NYHA Class I ) ischemic heart failure Subject age 18 , legal age give inform consent specific country national law Subject willing capable providing inform consent Subject willing capable comply visit procedure define protocol Subjects document permanent complete AV block Subjects permanent chronic atrial fibrillation ( AF ) AF time enrollment Subjects previously receive cardiac resynchronization therapy pacing leave ventricle Subjects active heart transplant list receive ventricular assist device ( VAD ) Life expectancy shorter 12 month due medical condition ( e.g. , cancer , uremia , liver failure , etc… ) Subject know suspected sensitivity dexamethasone acetate ( DXA ) Subject enrol concurrent clinical study , exception local mandatory governmental registry observational studies/registries , without write approval Boston Scientific Women childbearing potential plan become pregnant course trial Subjects currently require dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>